Baidu
map
EUR REV MED PHARMACO 润色咨询

European Review for Medical and Pharmacological Sciences

出版年份：1997 年文章数：6913 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：28.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2024-05-21 145aa4a9m26暂无昵称 来自浙江省

    终于被踢咯

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2024-03-26 145aa4a9m26暂无昵称 来自浙江省

    已经 on hold了，马上要被踢了

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2023-05-09 ms7000000507856696 来自江苏省

    审稿速度:1.0 | 投稿命中率:95.0
    偏重的研究方向：综合性期刊
    经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30
    %。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教

    12

    展开12条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2024-03-05 ms7000001027533891 来自安徽省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向：临床
    经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2019-12-01 14766288m61暂无昵称

    这个文章是不是只有under consideration的状态呀？

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2023-10-29 ms4000001373859908 来自北京

    请问一下Under consideration会持续多久呢？

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2023-11-20 ms4000001373859908 来自北京

    偏重的研究方向：生信
    经验分享：这个返修后underconsideration要多久？

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2023-10-20 ms4000001373859908 来自北京

    审稿速度:24.0 | 投稿命中率:5.0
    偏重的研究方向：生信
    经验分享：Under consideration需要多久？

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-11-25 ms7000001976046291 来自上海

    请问有大佬分享一下这个杂志的endnote格式吗 非常感谢

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2205887, encodeId=44ab220588e79, content=终于被踢咯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue May 21 18:40:10 CST 2024, time=2024-05-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2195483, encodeId=ab86219548354, content=已经 on hold了，马上要被踢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b9215078520, createdName=145aa4a9m26暂无昵称, createdTime=Tue Mar 26 19:49:52 CST 2024, time=2024-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2131127, encodeId=748a213112e21, content=审稿速度:1.0 | 投稿命中率:95.0<br>偏重的研究方向：综合性期刊<br>经验分享：欧洲药理学这个杂志在目前这个大环境下算是不错的期刊了，大家一定不要停留在老思维。首先发文量不高，不像FRONTIERS，MDPI，Hindawi等动辄发表6000-8000,甚至年发文量过万。第二，中国人发表比例不高，大约只有20-30<br>%。第三，特刊几乎没有，都是以普刊的形式发表。之前出事的杂志或者说是预警的杂志无一例外要么是大量的特刊捞钱，国人发表占比80%以上，发文量惊人。而欧洲药理学不存在诸如此类的情况。本人在欧洲药理学发表了很多篇论文，有需要了解审稿各个阶段状态的战友都可以私信我的，这个期刊的投稿和发表还是有一些窍门的，在下不吝赐教, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ef6490901, createdName=ms7000000507856696, createdTime=Tue May 09 11:41:52 CST 2023, time=2023-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2191209, encodeId=5f32219120986, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：临床<br>经验分享：这个杂志投稿后邮件只发给通讯作者，而不给其他人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8359127854, createdName=ms7000001027533891, createdTime=Tue Mar 05 19:24:12 CST 2024, time=2024-03-05, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=580787, encodeId=8497580e8798, content=这个文章是不是只有under consideration的状态呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=139, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c08d5213785, createdName=14766288m61暂无昵称, createdTime=Sun Dec 01 00:00:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165557, encodeId=6b43216555e38, content=请问一下Under consideration会持续多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Sun Oct 29 14:55:28 CST 2023, time=2023-10-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2169847, encodeId=1997216984eb1, content=偏重的研究方向：生信<br>经验分享：这个返修后underconsideration要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Mon Nov 20 22:47:34 CST 2023, time=2023-11-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2163896, encodeId=5f6d216389610, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：生信<br>经验分享：Under consideration需要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07ce6584759, createdName=ms4000001373859908, createdTime=Fri Oct 20 08:53:15 CST 2023, time=2023-10-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2102665, encodeId=4210210266517, content=请问有大佬分享一下这个杂志的endnote格式吗 非常感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b406582144, createdName=ms7000001976046291, createdTime=Fri Nov 25 23:02:42 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1192790, encodeId=ece81192e902a, content=偏重的研究方向：临床药理<br>经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Feb 12 21:17:49 CST 2022, time=2022-02-12, status=1, ipAttribution=)]
    2022-02-12 第五先生

    偏重的研究方向：临床药理
    经验分享：这杂志，选快速通道，会加快审稿速度吗，还是只是加快了接收后的出版速度

    8

    展开8条回复
共356条页码: 1/36页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map